StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.46−0.06 (-1.70%)

Close on Nov 17, 2026Market cap $224.08MP/E –Yield –

Immuneering operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Immuneering's operating cash flow for the twelve months ending Sep 30, 2026 was -$61.56M. For fiscal 2025 it was -$45.34M. The highest annual figure on record is -$14.62M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.34M–
FY2024Dec 31, 2024-$55.00M–
FY2023Dec 31, 2023-$48.97M–
FY2022Dec 31, 2022-$44.10M–
FY2021Dec 31, 2021-$30.85M–
FY2020Dec 31, 2020-$14.62M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$16.79M–
Q2 FY2026Jun 30, 2026-$16.50M–
Q1 FY2026Mar 31, 2026-$18.43M–
Q4 FY2025Dec 31, 2025-$9.84M–
Q3 FY2025Sep 30, 2025-$11.98M–
Q2 FY2025Jun 30, 2025-$9.45M–
Q1 FY2025Mar 31, 2025-$14.08M–
Q4 FY2024Dec 31, 2024-$14.51M–
Q3 FY2024Sep 30, 2024-$13.47M–
Q2 FY2024Jun 30, 2024-$11.53M–
Q1 FY2024Mar 31, 2024-$15.49M–
Q4 FY2023Dec 31, 2023-$11.78M–
Q3 FY2023Sep 30, 2023-$12.03M–
Q2 FY2023Jun 30, 2023-$10.75M–
Q1 FY2023Mar 31, 2023-$14.42M–
Q4 FY2022Dec 31, 2022-$11.75M–
Q3 FY2022Sep 30, 2022-$10.62M–
Q2 FY2022Jun 30, 2022-$9.45M–
Q1 FY2022Mar 31, 2022-$12.28M–
Q4 FY2021Dec 31, 2021-$9.24M–
Q3 FY2021Sep 30, 2021-$9.03M–
Q2 FY2021Jun 30, 2021-$6.44M–
Q1 FY2021Mar 31, 2021-$6.14M–
Q4 FY2020Dec 31, 2020-$5.45M–
Q3 FY2020Sep 30, 2020-$3.49M–

More Immuneering figures

See a number that looks wrong?